Optimisation of treatments for heart failure with reduced ejection fraction in routine practice: a position statement from a panel of experts
N Girerd, C Leclercq, O Hanon, A Bayés-Genís… - Revista Española de …, 2023 - Elsevier
Major international practice guidelines recommend the use of a combination of 4 medication
classes in the treatment of patients with heart failure with reduced ejection fraction (HFrEF) …
classes in the treatment of patients with heart failure with reduced ejection fraction (HFrEF) …
[HTML][HTML] Angiotensin Receptor Blocker-Neprilysin Inhibitor for Heart Failure with Reduced Ejection Fraction
D Nasrallah, A Abdelhamid, O Tluli… - Pharmacological …, 2024 - Elsevier
Heart failure with reduced ejection fraction (HFrEF) is a clinical syndrome characterized by
volume overload, impaired exercise capacity, and recurrent hospital admissions. A major …
volume overload, impaired exercise capacity, and recurrent hospital admissions. A major …
Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy
Aims Renin-angiotensin system (RAS) and natriuretic peptides system (NPS) perturbations
govern the development of diabetic nephropathy (DN). Hence, in search of a novel therapy …
govern the development of diabetic nephropathy (DN). Hence, in search of a novel therapy …
Simultaneous inhibition of neprilysin and activation of ACE2 prevented diabetic cardiomyopathy
Abstract Background Neprilysin inhibitors (NEPi) are assisting the renin-angiotensin system
(RAS) inhibitors in halting diabetic cardiomyopathy (DCM). Away from conventional tactic, a …
(RAS) inhibitors in halting diabetic cardiomyopathy (DCM). Away from conventional tactic, a …
Effects of angiotensin receptor neprilysin inhibitors on inducibility of ventricular arrhythmias in rats with ischemic cardiomyopathy
JY Huo, WY Jiang, C Chen, R Chen, TT Ge… - International Heart …, 2019 - jstage.jst.go.jp
The aims of the present study were to investigate the effects of angiotensin receptor
neprilysin inhibitors (ARNi) on the susceptibility of ventricular arrhythmias (VAs) in rats with …
neprilysin inhibitors (ARNi) on the susceptibility of ventricular arrhythmias (VAs) in rats with …
[HTML][HTML] Recurrent hypotension induced by sacubitril/valsartan in cardiomyopathy secondary to Duchenne muscular dystrophy: A case report
JM Li, H Chen - World Journal of Clinical Cases, 2019 - ncbi.nlm.nih.gov
BACKGROUND Duchenne muscular dystrophy (DMD), which is caused by a
mutation/deletion in the dystrophin gene on the X-chromosome, is the most common type of …
mutation/deletion in the dystrophin gene on the X-chromosome, is the most common type of …
[HTML][HTML] The emerging role of sacubitril/valsartan in pulmonary hypertension with heart failure
Y Xu, B Yang, J Hui, C Zhang, X Bian, M Tao… - Frontiers in …, 2023 - frontiersin.org
Pulmonary hypertension due to left heart disease (PH-LHD) represents approximately 65%–
80% of all patients with PH. The progression, prognosis, and mortality of individuals with left …
80% of all patients with PH. The progression, prognosis, and mortality of individuals with left …
Optimización de los tratamientos de la insuficiencia cardiaca con fracción de eyección reducida en la práctica diaria: propuesta de un grupo de expertos
N Girerd, C Leclercq, O Hanon, A Bayés-Genís… - Revista Española de …, 2023 - Elsevier
El tratamiento de los pacientes con insuficiencia cardiaca con fracción de eyección reducida
(IC-FEr) con una combinación de 4 clases de fármacos se recomienda en las principales …
(IC-FEr) con una combinación de 4 clases de fármacos se recomienda en las principales …
[HTML][HTML] Первый опыт применения валсартана/сакубитрила у женщин с сердечной недостаточностью и раком молочной железы, получающих адъювантную …
СГ Канорский, ВП Павловец - Медицинский совет, 2019 - cyberleninka.ru
Цель. Сравнение кардиопротективной эффективности валсартана/сакубитрила и
кандесартана у женщин с сердечной недостаточностью (СН) и исходно сниженной …
кандесартана у женщин с сердечной недостаточностью (СН) и исходно сниженной …
Progress in drug treatment of elderly chronic heart failure
S Zhang, F Liu - Aging Pathobiology and Therapeutics, 2020 - luolan-bio.com
Chronic heart failure (CHF) is a serious public health problem in the world, which occurs
mostly in the elderly, with extremely high morbidity and mortality. The physiological changes …
mostly in the elderly, with extremely high morbidity and mortality. The physiological changes …